Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 8/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 5/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.37 |
| ▸ | MMP9 | P14780 | 2/20 | 0.37 |
| ▸ | CTSS | P25774 | 2/20 | 0.37 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4955709 | 0.85 | CTSK (0.34) | ITGB3ITGA2BHDAC1HDAC4HDAC6 | |
| SCHEMBL4955696 | 0.84 | CTSK (0.37) | ITGB3ITGA2BHDAC1HDAC4HDAC6 | |
| SCHEMBL4910519 | 0.83 | ITGB3 (0.43) | ITGB3ITGA2BHDAC1HDAC4HDAC6 | |
| SCHEMBL1733549 | 0.77 | KMT2A (0.39) | CTSKCTSSHDAC8 | |
| SCHEMBL22493536 | 0.74 | ITGB3 (0.38) | ITGB3ITGA2BCTSKCTSS | |
| SCHEMBL22493537 | 0.74 | ITGB3 (0.38) | ITGB3ITGA2BCTSKCTSS | |
| SCHEMBL23608150 | 0.74 | CTSK (0.49) | ITGB3ITGA2BHDAC1HDAC4HDAC6 | |
| SCHEMBL2804552 | 0.74 | CTSK (0.49) | ITGB3ITGA2BHDAC1HDAC4HDAC6 | |
| SCHEMBL7150850 | 0.74 | CTSK (0.49) | ITGB3ITGA2BHDAC1HDAC4HDAC6 | |
| SCHEMBL376450 | 0.74 | FOLH1 (0.53) | ITGB3ITGA2BHDAC1HDAC4HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470855-B2 | Dual-use peptidase inhibitors as prodrugs for a therapy of inflammatory and other diseases | IMTM GMBH (DE) | 2013-06-25 | — | — | US | disclosed |
| EP-1948627-B1 | NOVEL DUAL PEPTIDASE INHIBITORS AS PRODRUGS FOR THE THERAPY OF INFLAMMATORY AND OTHER DISORDERS | IMTM GMBH (DE) | 2012-03-14 | — | — | EP | disclosed |
| US-20090124667-A1 | Novel Dual-Use Peptidase Inhibitors as Prodrugs for a Therapy of Inflammatory and Other Diseases | IMTM GMBH (DE) | 2009-05-14 | — | — | US | disclosed |
| EP-1948627-A1 | NOVEL DUAL PEPTIDASE INHIBITORS AS PRODRUGS FOR THE THERAPY OF INFLAMMATORY AND OTHER DISORDERS | IMTM GmbH (DE) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007057128-A1 | NOVEL DUAL PEPTIDASE INHIBITORS AS PRODRUGS FOR THE THERAPY OF INFLAMMATORY AND OTHER DISORDERS | IMTM GMBH (DE) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124667-A1 | Novel Dual-Use Peptidase Inhibitors as Prodrugs for a Therapy of Inflammatory and Other Diseases | CTSL, DAO, PEPD | ITGB3 3826/4885ITGA2B 2892/4885HDAC1 1871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.